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The HIV-1 transactivator protein Tat is a critical regulator of
HIV transcription primarily enabling efficient elongation of
viral transcripts. Its interactions with RNA and various host
factors are regulated by ordered, transient post-translational
modifications. Here, we report a novel Tat modification, mono-
methylationat lysine71(K71).WefoundthatLys-71monometh-
ylation (K71me) is catalyzed by KMT7, a methyltransferase that
also targets lysine 51 (K51) in Tat. Using mass spectrometry, in
vitro enzymology, and modification-specific antibodies, we
found that KMT7 monomethylates both Lys-71 and Lys-51 in
Tat. K71me is important for full Tat transactivation, as KMT7
knockdown impaired the transcriptional activity of wild type
(WT) Tat but not a Tat K71R mutant. These findings underscore
the role of KMT7 as an important monomethyltransferase reg-
ulating HIV transcription through Tat.
The HIV-1 epidemic remains a global health problem despite
the growing availability of potent antiretroviral therapies.
These therapies are not curative, as latent, transcriptionally
silent virus can spontaneously reactivate from sanctuaries and
rapidly rekindle viral infection after withdrawal of therapy
(1–3). Therefore, the molecular mechanisms of the activation
and suppression of HIV transcription are of great interest.
HIV encodes its own viral transactivator, Tat, which activates
HIV transcription and facilitates its own production in a posi-
tive feedback loop. Tat is a small protein, typically found in a
full-length form of 101 amino acids (aa)3 or as a splice variant
(72 aa) encoded only by the first exon of the tat open reading
frame. Both isoforms efficiently transactivate the HIV pro-
moter in the 5 long terminal repeat (LTR). Tat interacts with
the positive transcriptional elongation factor b (P-TEFb), and
viral RNA through several well-characterized domains that can
be found in its one-exon form: a cysteine-rich domain (aa
22–37) and a highly conserved core domain (aa 41– 48), both of
which participate in binding of P-TEFb (4 – 6). The neighboring
arginine-rich motif (ARM; aa 49 –57) interacts with a specific
stem-loop RNA structure called transactivation response ele-
ment (TAR) located in the 5 extremities of all viral transcripts
(7–10). Specific binding of the Tat ARM to TAR requires the
coordinated binding of P-TEFb to Tat, as the cyclin T1 subunit
of P-TEFb binds both the Tat cysteine-rich and core domains
and loop sequences of TAR (11). C-terminal to these well-char-
acterized domains is a glutamine-rich motif (aa 59 –72). When
expressed as a peptide, this region adopts a conserved -helical
structure that is stabilized upon binding to TAR RNA and is
implicated in T-cell apoptosis (12, 13).
Tat is regulated by a number of post-translational modifica-
tions including phosphorylation, acetylation, methylation, and
polyubiquitylation (14). The Tat ARM is highly modified at
lysine and arginine residues. These modifications, including
acetylation of Lys-50/51 and methylation of Lys-51 and Arg-52/
53, regulate TAR and P-TEFb binding positively (K51me) or
negatively (K50ac/K51ac; R52me2/R53me2) (15–20). The role
of post-translational modifications in the glutamine-rich motif
is still unclear. Several phosphorylation sites in this domain
(Ser-62, Thr-64, Ser-68) enhance transcriptional activity, but
are not well conserved among viral isolates (21, 22). In contrast,
lysine 71 is a highly conserved residue found in 74% of HIV-1
isolates across all clades reported in the HIV-1 sequence com-
pendium (22). At this residue, polyubiquitylation at Lys-71 is
required for full transactivation, but does not affect Tat stability
(23).
We previously reported that Lys-51, within the Tat ARM, is
monomethylated (K51me) by the methyltransferase KMT7
(also called SET7/9) (17). Monomethylation at Lys-51 en-
hanced TAR RNA binding of Tat, and increased trimolecular
complex formation between Tat, TAR, and P-TEFb. Interest-
ingly, KMT7 itself was found to bind TAR RNA in band-shift
assays, indicating that it could be recruited to the HIV promoter
before Tat was produced (17). In in vitro methylation assays of
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ARM peptides (aa 44 –59), we observed that that KMT7 fails to
methylate residues other than Lys-51 in Tat (17, 18). However,
when we conducted the same in vitro assays using purified one-
exon Tat proteins (Tat72), we observed additional methylation
on Tat indicating that one or more additional methylation sites
existed outside of the ARM region. In this study, we sought to
further understand the role of KMT7 in the Tat transcription
cycle by identifying and characterizing the additional modifica-
tion(s). We hypothesized that understanding the full extent of
Tat methylation would bring new insight into the regulation of
Tat function and the role of KMT7 as an HIV-1 transcriptional
cofactor.
Results
In Vitro Methylation of Tat72 Peptides Reveals a Novel KMT7
Methylation Site at Lys-71—To determine whether Lys-51 is
the only KMT7 methylation site in Tat, we performed in vitro
methylation reactions with Tat peptides spanning aa 1–72
(Tat72). We observed substantial incorporation of [3H]S-ad-
enosyl methionine ([3H]SAM) in Tat72 proteins carrying
monomethylated Lys-51, indicating additional KMT7 methyl-
ation sites in Tat (Fig. 1, A and B). In Tat72 proteins with an
acetyl group at Lys-50, [3H]SAM incorporation was also slightly
decreased. This is consistent with previous observations that
this modification reduces access of KMT7 to Lys-51 (18).
To specifically identify additional KMT7 methylation sites in
Tat, we performed in vitro methylation reactions using non-
radiolabeled SAM and subjected modified Tat proteins to
MALDI-TOF MS/MS analysis developed to analyze Tat (18).
This analysis revealed monomethylation at a single additional
site, Lys-71 (Fig. 1, C and D, supplemental Table S-1) in two
distinct peptides in reactions with KMT7, but not in reactions
with a control enzyme KMT1E (also called SETDB1) or no
enzyme (Fig. 1C). In one peptide, only Lys-71 was monomethy-
FIGURE 1. HIV-1 Tat is monomethylated at Lys-71 by KMT7. In vitro methylation assays were done with 3 g of synthesized Tat72 proteins that were
unmodified, acetylated (K50ac), methylated (K51me), or both acetylated and methylated, with or without 1 g of recombinant KMT7 in the presence of
[3H]SAM. A, top, representative autoradiogram. This image is uncropped and from one gel; the difference in background is an imperfection of the film. Bottom,
Coomassie Blue stain for Tat. Molecular weight markers are noted in kilodaltons (kDa) B, quantification of three autoradiograms with ImageJ (mean  S.E.). C,
in vitro methylation assays on unmodified Tat proteins with indicated enzymes were subjected to MS, shown are the zoomed regions containing Tat ions
corresponding to aa 48 –72. Boxed in red are peaks indicating modified Tat ions. D, MS/MS spectra of the ions boxed in 1C, and their corresponding peptide
sequences. Ion annotations are found in supplemental Table S-1.
KMT7 Monomethylates Tat at Lys-71
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lated (Fig. 1D, left); in the other, both Lys-51 and Lys-71 were
monomethylated (Fig. 1D, right). Neither Lys-51 nor Lys-71
was dimethylated, underscoring the function of KMT7 as a
monomethyltransferase in Tat.
KTM7 Modifies Tat at Lys-71 in Vitro—Next, we tested
whether pre-modification of Lys-71 in Tat72 peptides affects in
vitro methylation by KMT7. Premethylation of Lys-71 mark-
edly decreased [3H]SAM incorporation while Lys-51 pre-meth-
ylation had a lesser effect. Finally, premethylation of both
Lys-51 and Lys-71 abolished methylation of Tat, demonstrating
that there are no additional targets for KMT7 in Tat (Fig. 2A).
These findings support Lys-51 and Lys-71 as the sole sites for
KMT7 monomethylation in Tat72.
To better quantify dynamics of KMT7-mediated methyla-
tion of Tat72 proteins, we used pre-modified Tat proteins in a
modified kinetic radiometric assay (24). After testing for line-
arity with time and KMT7 enzyme concentrations, kinetics
assays were performed with various concentrations of Tat72
proteins (Fig. 2B). Methyltransferase activity was hyperbolic,
and all Tat proteins except the Tat K51/K71me doubly modi-
fied form followed Michaelis-Menten kinetics. The doubly
modified form had very little methylation, consistent with our
observations using autoradiography (Fig. 2A).
The catalytic turnover (kcat) and Michaelis constant (Km) of
the Tat K51me proteins were 62% lower relative to the unmod-
ified proteins. Interestingly, the kcat of the K71me proteins
decreased by 83% but the Km decreased only 21%. Thus, the
methylation efficiency (kcat/Km) on K51me protein was similar
to that of the unmodified protein, but the K71me was 78% less
than that on control proteins. Furthermore, almost no methyl-
ation was detected in the K51/K71me protein. Together, these
data support the model that Lys-71 is preferred over Lys-51 as a
target for KMT7 in Tat (Fig. 2, B and C) and there are no addi-
tional sites in Tat72 for KMT7 monomethylation.
MS of Tat Purified from HEK293T and Jurkat A2 Cells
Reveals Monomethylation at Lys-71 exists in Vivo—To examine
Lys-71 methylation in vivo, we coexpressed Tat101 bearing a
C-terminal FLAG tag together with either a KMT7 or empty
vector in HEK293T cells for 24 h. We first purified Tat from
lysates by FLAG immunoprecipitation, followed by SDS-PAGE
separation. The separated Tat protein was subjected to
MALDI-TOF MS/MS, which showed that Lys-71 was monom-
ethylated only when KMT7 was overexpressed (Fig. 3, A and B;
supplemental Table S-2). This suggests that the fraction of Tat
that is naturally monomethylated at Lys-71 in HEK293T cells
may be small compared with the unmodified form.
Next, we analyzed Tat methylation in J-Lat A2 T cells, in
which expression of FLAG-tagged Tat101 is controlled by its
natural promoter and induced by stimuli such as tumor necro-
sis factor  (TNF) (25). Tat expression was induced with
TNF, FLAG-affinity-purified, and analyzed by MS. We iden-
tified a peptide fragment of 1032.627 Da, corresponding to Tat
aa 70 –78 with a monomethyl group at Lys-71 (Fig. 3C). MS/MS
confirmed the monomethylation at Lys-71 (Fig. 3D, supple-
mental Table S-2). Together these findings show that Tat
Lys-71 is monomethylated in Jurkat T cells under conditions
mimicking natural HIV infection and that this modification can
be induced by KMT7 overexpression in 293T cells.
Generating Antibodies Specific for K71me—We confirmed
these results using newly generated modification-specific poly-
clonal antibodies. We previously published methods to pro-
duce and characterize mono-, di-, and tri-methyl Tat-specific
antibodies at Lys-51 (26). Following these methods, we focused
on two chemically synthesized K71me 11-mer peptides (type 1
and type 2) (Fig. 4A). Peptide 1 (aa 63–72) ends with the first
exon, and peptide 2 (aa 67–76) spans both Tat exons. Cysteine
residues are added to the C-terminal end of the peptides for
purification purposes as described (26). After antigen-purifica-
tion of the modification-specific antibodies, we performed dot-
blot analysis of various chemically modified Tat proteins (Fig.
4B). Type 1 antibodies reacted with all synthetic Tat72 proteins
(WT, K51me, K71me, K50Ac, and K51/K71me), but type 2
antibodies detected only the K71me Tat72 proteins. Similar
results were obtained by SDS-PAGE and Western blotting (Fig.
4C). The type 2 antibodies were highly specific for Tat72 pro-
teins carrying a monomethyl group at K71, and the type 1 anti-
FIGURE 2. KMT7 preferentially monomethylates Tat Lys-71 in vitro. A, reactions were done as in Fig. 1A with 2 g of synthesized Tat72 proteins that were
unmodified, monomethylated at Lys-51 or Lys-71 or both, and incubated with 0, 1, or 2 g of purified KMT7 in the presence of [3H]SAM. Top, representative
autoradiogram. Bottom, Coomassie Blue stain for Tat and KMT7. B, kinetic assays were done with indicated concentrations of Tat peptides and 1 g of
recombinant KMT7. Assays were conducted in triplicate; error bars indicate S.E. C, activity calculated by fitting data to Michaelis-Menten equation with
SigmaPlot 11 after correction for methylation in the control reactions with either the enzyme or the substrate removed. ND, not determined in doubly modified
peptides.
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bodies recognized all Tat proteins. Type 2 antibodies detected
several cellular bands in whole cell lysates (data not shown).
Therefore, for further analysis, we used type 2 TatK71me anti-
bodies on FLAG-immunopurified samples.
Detecting Tat K71me by Western Blot Analysis in Vivo—To
confirm the specificity of the type 2 antibodies in vivo, we over-
expressed WT or FLAG-tagged Tat101 proteins carrying muta-
tions at Lys-71, Lys-51, or Lys-50 in 293T cells. After FLAG
immunoprecipitation, we detected K71me Tat only in WT,
Lys-50 and Lys-51 mutants, but not in Lys-71 mutants (Fig. 5A).
This finding indicates that endogenous KMT7 is sufficient to
methylate Lys-71 in cells. Furthermore, we were able to
increase TatK71me by coexpressing Tat101 with WT KMT7
relative to coexpression with a catalytically inactive KMT7
mutant (H297A). Importantly, no change in methylation was
observed on the K71R mutant (Fig. 5B).
Next, we determined whether the K71me antibodies are able
to detect Tat72 in T cells. For this, we used an HIV-1 mini-
genome to generate Jurkat cell lines that stably express Tat72,
as described for the Jurkat A2 cells (27). We sorted for cells with
high-level GFP expression, and transduced them with lentivi-
ruses containing one of two shRNAs targeting KMT7 (a and b)
or a scrambled shRNA (Scr). The lentiviral constructs also con-
tained a puromycin resistance gene, which allowed us to select
for shRNA-expressing cells. After selection, shRNA-expressing
cells were lysed and subjected to FLAG immunoprecipitation,
and Tat K71me levels were determined by Western blotting
(Fig. 5C). Knockdown of KMT7 was robust; in accordance, Tat
K71me levels were reduced by 51% in cells treated with the
KMT7b shRNA and by 28% in cells treated with KMT7a shRNA
(Fig. 5B, bottom). These results underscore the role of KMT7 as
an important K71 methyltransferase for both forms of Tat in T
cells. Since a substantial amount of Tat remained methylated at
Lys-71 despite the knockdown, we suspect that a small residual
pool of KMT7 may be sufficient to modify a proportion of Tat
proteins, or perhaps another enzyme is capable of monomethy-
lating Tat in cells.
K71me Does Not Affect Tat Half-life—A number of substrates
modified by KMT7 are altered in their stability by downstream
changes in their polyubiquitylation (28). Because Lys-71 has
previously been reported as a site for polyubiqitination (23), we
examined whether Lys-71 methylation by KMT7 affects the
stability of Tat in Jurkat cell lines expressing fluorescent
Tat101-Dendra fusion proteins generated for this purpose (25).
The Tat-Dendra system has been used to determine the Tat
half-life in flow cytometry and microscopy studies (29, 30). To
knock down KMT7, we transduced Tat-Dendra cells with the
lentiviral vectors expressing scrambled or KMT7b shRNAs
used for Fig. 5B. After puromycin selection, we monitored
effects of KMT7 knockdown on Tat half-life only in successfully
transduced cells. Knockdown of KMT7 was confirmed by
Western blotting (Fig. 6B). Expression of WT or K71R Tat-
Dendra proteins was induced with TNF. After 16 –20 h of
TNF treatment, cycloheximide was added to inhibit de novo
production of Tat. Cells were fixed at various times, and Tat
expression was determined by flow cytometry of Dendra (Fig.
6A). Tat stability did not differ in cells transduced with control
and KMT7 shRNAs, excluding any prominent effect of K71
FIGURE 3. In vivo detection of Tat K71me in HEK293T and Jurkat A2 cell lines. A, WT Tat101-FLAG and KMT7 were overexpressed in HEK293T cells and
analyzed by MS after FLAG affinity purification. A zoomed region of the initial MS spectrum shows the K71me containing ion found in the presence of KMT7
overexpression, but not the control. The spectrum is representative of two independent experiments. B, MS/MS of the ion containing K71me indicated by a red
box in 3A and sequence of the fragment. C, Tat101-FLAG was FLAG-affinity-purified from Jurkat A2 cells after induction with TNF and analyzed by MS.
Depicted is the full spectrum with a Tat K71me-carrying ion (aa 70 –78). D, MS/MS of the ion containing K71me indicated by a red box in 3C and sequence of the
fragment. Ion annotations are found in supplemental Table S-2.
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methylation on Tat stability (Fig. 6C). In cells expressing scram-
bled shRNA, the K71R Tat mutant had a slightly longer half-life
than WT Tat (10.9 versus 9.0 h, p  0.043). However, time-lapse
single-cell microscopy of Tat-Dendra cells revealed no statisti-
cal difference in the half-lives of WT and K71R Tat in the
absence of shRNAs (Fig. 6D). Together, these data affirm pre-
vious findings that Lys-71 modifications are not involved in Tat
protein stability (29).
Lys-71 Methylation Enhances Tat Transactivation—Previ-
ously, we found that KMT7-mediated monomethylation of Tat
Lys-51 enhances interactions between Tat and TAR RNA and
P-TEFb and activates HIV gene expression (17). To assess the
effect of Lys-71 monomethylation on Tat transactivation, we
transfected plasmids expressing WT or mutant Tat101 (K51R,
K71R, or K51/71R) into TZMBL cells, which express firefly
luciferase from the integrated HIV LTR when functional Tat is
expressed (31). Transactivation was 50% lower in the Tat
K51R and Tat K71R mutants than in WT Tat at three different
plasmid concentrations, confirming that these residues are
important for Tat transactivation (17, 23). Transactivation was
almost completely lost when both Lys-51 and Lys-71 were
mutated, underscoring their combined importance in Tat
transactivation. All Tat proteins were expressed at similar levels
as confirmed by Western blot analysis (Fig. 7A).
To test whether monomethylation at Lys-71 by KMT7 con-
tributes to Tat transactivation, we knocked down KMT7
expression using KMT7b shRNAs in TZMBL cells before trans-
fection with WT Tat or K71R mutant Tat101. Knockdown of
KMT7 decreased the transcriptional activity of Tat WT but had
no effect on K71R mutant Tat. Evidently, KMT7 activates Tat
transactivation, at least in part, through Lys-71 monomethyla-
tion (Fig. 7B). Knockdown of KMT7 was confirmed by Western
blotting(Fig.7B).ThesefindingsindicatethatLys-71monometh-
ylation, rather than regulating Tat stability, plays a positive role
in the transcriptional activity of Tat.
Discussion
HIV-1 Tat is a potent viral transactivator that undergoes
extensive post-translational modifications. Here, we expand
the role of KMT7 in Tat function by identifying Lys-71 as a
second monomethylation site. We found that Lys-71 is
monomethylated in both functional HIV-1 Tat101 and Tat72
FIGURE 4. Generation of K71me-specific antibodies. A, schematic of the
synthetic methylated peptides used as antigens to generate K71me Tat anti-
bodies. B, dot blots with synthetically modified Tat72 proteins (K51me,
K71me, K51/K71me, and K50ac) incubated with antigen-purified type 1 or
type 2 K71me antibodies. C, Western blot analysis of indicated Tat72 proteins
(1, 10, 100 ng each) with type1 antibodies (top) and type 2 antibodies
(bottom).
FIGURE 5. Detection of K71me Tat methylation in vivo. Lysates from 293T
or Jurkat cells were FLAG-immunopurified and blotted with indicated anti-
bodies including type 2 Tat K71me antibodies. A, Western blot analysis of
indicated Tat101-FLAG mutants expressed in HEK293T cells. B, Western blot
analysis of Wt or K71R Tat101-FLAG co-expressed with Wt or catalytically
inactive KMT7 mutant in HEK293T cells. Tat Wt and K71R blots were cropped
from the same gel and had the same exposure times. C, Western blot analysis
of FLAG-purified Tat72-FLAG isolated from stable cells lines transduced with
shRNAs against KMT7 (KMT7a or KMT7b) or a scrambled control. Western
blots were performed with indicated antibodies. ImageJ was used for
quantification.
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splice variants, underscoring its importance throughout the
HIV-1 life cycle. We identified KMT7 as a robust Tat Lys-71
monomethyltransferase in both in vitro and in vivo assays.
Although KMT7 substrates often have perturbed stability,
mutation of Lys-71 or knock down of KMT7 did not affect the
stability of Tat. Instead, Lys-71 monomethylation is important
for the transcriptional activity of Tat through a yet unresolved
mechanism.
Notably, in vitro methylation and enzymology experiments
indicate that the preferred methylation site of KMT7 is Lys-71
rather than Lys-51, previously identified as a target of KMT7.
Although KMT7 has no known stringent site specificity, two
consensus sequences in KMT7 targets have been described:
(K,R)2-(S,T,A)1-Kme0-X1 (where X is a polar residue) and
a newer sequence (G,R,H,K,P,S,T)3-(KR)2-(SK,Y,A,R,
T,P,N)1-Kme0-(Q,N)1-(A,Q,G,M, S,P,T,Y,V)2 (32, 33).
Comparing the sequences of K71me (S3L2S1Kme0Q1-
P2) and K51me (G3R2K1Kme0R1R2), Lys-71 is more
closely aligned with the newer consensus sequence than Lys-51,
possibly explaining why Lys-71 was the preferred target in our
in vitro studies (32).
Our finding that KMT7 methylates Tat at two sites is consistent
with reports that KMT7 often has multiple targets within individ-
ual substrates. For example, the RelA subunit of the NF-B tran-
scription factor has three KMT7 monomethylation sites (K37me,
K314me, K315me) and the PCAF acetyltransferase has two
(K78me, K89me) (34–36). Since the addition of a monomethyl
group is a rather subtle modification (14 Da), it is likely that mul-
tiple monomethylation sites act in concert to mediate appropriate
regulation of the substrate protein by KMT7.
FIGURE 6. Lys-71 mutation or KMT7 knockdown does not affect Tat stability. A, flow cytometry histograms showing mean Tat-Dendra fluorescence (MFI)
at indicated times (0 – 8 h) in WT cells stably transduced with KMT7b or scrambled shRNAs and treated with cycloheximide. B, Western blot analysis confirms
knockdown of KMT7 in Tat-Dendra J-Lat lysates after puromycin selection. C, measurements of Tat half-life by flow cytometry. MFIs were normalized to t  0
after removing background, natural log transformed, and plotted over time as mean ln(MFI)  S.E. of four independent experiments in cells transduced with
lentiviruses containing KMT7b or scrambled shRNAs and expressing WT or K71R Tat. D, time-lapse single cell microscopy of WT or K71R Tat-Dendra J-Lats each
point represents the MFI of 50 independent cells that were tracked for at least 2 h.
KMT7 Monomethylates Tat at Lys-71
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Two main consequences of KMT7-mediated methylation
have emerged: alteration of protein stability and the regulation
of interactions between nucleic acids and proteins (32). The
oncogene p53 and estrogen receptor  are both stabilized upon
monomethylation by KMT7 (37, 38). In contrast, RelA of
NF-B and DNMT1 are both destabilized upon monomethlya-
tion of one or more sites by KMT7 (35, 39). One review
regarded KMT7 as a bona fide protein stability modifier, pro-
posing the presence of a methyl/ubiquityl switch that can
regulate the stability of substrates (28). However, polyubiquiti-
nation of Tat at Lys-71 has been linked to enhanced transcrip-
tional activity, not degradation (23). Indeed, we found that
KMT7 knockdown did not significantly affect the stability of
WT or K71R Tat.
Early structural studies of Tat isolates suggested that the glu-
tamine-rich motif (aa 59 –72) has a degenerate -helical struc-
ture, consistent across different Tat isolates and adopted in the
presence of TAR RNA (12). This structure is adopted partially
through conserved glutamine-RNA hydrogen bonds (Gln-60,
Gln-63, Gln-66, Gln-72) and an electrostatic interaction
between Lys-71 and the TAR phosphodiester backbone at
nucleotides 31–35 (12, 13). Lys-71 monomethylation could
thus enhance these interactions by stabilizing the electrostatic
interaction between Lys-71 and the TAR loop (13, 17). Previ-
ously, we showed that methylation of Lys-51 by KMT7 activates
appropriate Tat/TAR/P-TEFb binding (17). Lys-51 lies in the
ARM of Tat, which binds TAR RNA in the bulge region. There-
fore, methylation of Lys-51 and Lys-71 by KMT7 might coor-
dinately enhance the binding of TAR RNA to multiple residues
in Tat, potentially positioning the RNA properly with respect to
Tat and P-TEFb. Future experiments are necessary to explore
this model and elucidate the mechanism by which KMT7 acti-
vates Tat transactivation by monomethylating Lys-71.
Experimental Procedures
Materials—HEK293T, Jurkat, and TZMBL cells were ob-
tained from American Type Culture Collection. Anti-FLAG
M2 affinity gel (A2220) and anti-FLAG monoclonal rabbit anti-
bodies (F7425) were from Sigma-Aldrich. Tubulin antibodies
(ab15246) were from Abcam and KMT7 antibodies (Clone
5F2.3, 04-805) were from Millipore. KMT7 siRNAs (4392420)
were from ThermoFisher. Tat72 proteins (unmodified, Tat
K71me, Tat K51me, Tat K50Ac, and Tat K51/K71me) were
synthesized by PSL Peptide Specialty Laboratories (Heidelberg,
Germany). TNF (ThermoFisher, PHC3011) was resuspended
in water at 100 ng/l. Cycloheximide (MP Biomedicals,
02100183) was resuspended in water at 10 mg/ml.
In Vitro Methylation—Reactions were carried out with 3 g
of synthesized Tat peptides and 0, 1, or 2 g of purified KMT7
in a solution of 0.1 M Bicine, pH 8.2, 60 M [3H]SAM. After
incubating the mixtures for 18h at room temperature, the meth-
ylation reactions were run on 15% SDS-PAGE gels, which were
stained with Coomassie Blue, and destained overnight. Methy-
lation was detected by autoradiography (22-h exposure).
Mass Spectrometry—In vitro modified and in vivo purified
Tat peptides were analyzed by MALDI-TOF tandem mass
spectrometry (MS) as described (18).
Enzymology—Methyltransferase activity was measured with
a modified radiometric assay (24). Kinetic assays were per-
formed with various concentrations of synthetic Tat72 peptides
(unmodified, Tat K71me, Tat K51me, and Tat K51/K71me).
The 20-l reactions contained Tat peptides, 0.1 M Bicine, pH
8.2, 60 M [3H]SAM (3.4Ci/mmol), and 1 g of purified full-
length KMT7 (40). The reactions were incubated for 1 min at
37 °C. To terminate the reaction and ensure full precipitation of
the substrates, 0.5 ml of 10% TCA and 5 l of a bovine serum
albumin (BSA) solution (10 g/100 ml of water) were added.
After this addition the mixture was then vortexed, incubated on
ice for 3 min, and centrifuged at 14,000 rpm for 3 min. To
process the reaction, the protein pellets were washed with 150
l of 0.1 M NaOH, re-precipitated in TCA, vortexed and cen-
trifuged at 14,000 rpm for 3 min. The pelleted proteins were
dissolved in 50 l of formic acid, diluted by half with water,
mixed with 1.25 ml of Bio-Safe II scintillant (Research Products
International), and subjected to liquid scintillation. Activity
was calculated after correcting for methylation in control reac-
tions lacking either the enzyme or the substrate. The assays
were performed in triplicate, and the data were plotted and
fitted with SigmaPlot 11 (Systat Software) to the Michaelis-
Menten equation.
Tat K71me Antibody Purification—Peptides for antibody
synthesis (K71me1 Type 1, K71me1 Type 2; Fig. 4A) were syn-
thesized by PSL Peptide Specialty Laboratories and injected
FIGURE 7. Tat K71me regulates Tat transactivation. A, TZMBL cells were
transfected with increasing concentrations of plasmids (2, 5, and 10 ng)
expressing WT or mutant Tat101. Luciferase values are shown from four inde-
pendent experiments measured as fold expression over empty vector
(mean  S.E.). Western blot analysis was performed in cells transfected with
100 ng of Tat-FLAG plasmid and blotted with anti-FLAG antibodies. B, lucifer-
ase values in TZMBL cells transduced with KMT7b or scrambled shRNAs and
then transfected with WT or TatK71R Tat-expressing plasmids (20 ng). KMT7
knockdown is visualized by Western blotting. Values are mean  S.E. from
four independent experiments. Significance was calculated with a one-sided
t test. *, p 	 0.05.
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into rabbits and antibodies were purified from serum with anti-
genic peptides as described (26). Purified antibodies were
eluted under acidic conditions, resuspended in 1% BSA and
0.1% sodium azide, and stored at 80 °C.
Dot Blot Analysis of K71me Antibodies—Tat peptides were
serially diluted in water and spotted on a 0.2 M Hybond ECL
membrane. Membranes were air-dried, and nonspecific bind-
ing was blocked with nonfat dry milk (5 g/100 ml in TBST
consisting of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1%
Tween 20) for 1 h at room temperature. Membranes were incu-
bated with K71me antibodies diluted in blocking buffer for 1 h,
washed five times with TBST, then incubated with HRP-conju-
gated anti-rabbit IgG (Jackson ImmunoResearch) at a concen-
tration of 16 ng/ml in blocking buffer, washed 3–5 times with
TBST, and analyzed using standard ECL substrate.
Detection of K71me in Vivo—Tat mutants (K71A, K71R, K51/
71A, K51/71R) were generated by site-directed mutagenesis of
previously described Tat constructs (17). KMT7 expression
vectors (WT and H297A) were also previously described (17).
For experiments conducted in HEK293T cells, Tat constructs
(2 g) or Tat and KMT7 (2.5 and 6 g, respectively) were trans-
fected into cells using Lipofectamine 2000 and incubated for
24 h prior to lysis. For experiments conducted in Jurkat cells,
WT and K71R Tat72-expressing cells were produced as
described (27). After sorting, cells were transduced with lenti-
viruses containing control short hairpin RNAs (shRNAs) or
KMT7 shRNAs (KMT7a: GCACTTTATGGGAAATTTA;
KMT7b: GTAGCTGTGGGACCTAATA) and a puromycin
resistance cassette. After 1 week of puromycin selection at 2
g/ml, cells were lysed using IP-lysis buffer (150 mM NaCl, 50
mM Tris, pH 7.4, 1 mM EDTA, 0.5% v/v Nonidet P-40 substitute)
and Tat-FLAG was immunoprecipitated from 500 g of pro-
tein using anti-FLAG M2 affinity gel. Immunoprecipitated Tat
was analyzed using either anti-FLAG antibodies (0.16 g/ml) or
K71me antibodies (1.75 ng/ml) diluted in blocking buffer. After
washing, membranes were incubated with a HRP-conjugated
anti-rabbit antibody (160 ng/ml). All K71me Western blot anal-
ysis performed at least twice.
Measuring the Half Life of Tat—WT LTR-Tat101-Dendra
(LTD) constructs were subjected to site-directed mutagenesis
to generate the K71R mutation in Tat. WT or K71R LTD con-
structs, a lentiviral construct (pCMV-
R8.91) and VSV-G
pseudotyped envelope plasmid were co-transfected into
HEK293T cells to produce lentivirus, as described (41). Jurkat T
cells were infected with either WT or K71R LTD lentiviral vec-
tors to generate polyclonal J-Lat populations as described (25).
After resilencing of the LTR, LTD jurkats were infected with
KMT7b shRNAs and selected with puromycin for at least 1
week. For protein stability experiments, Tat expression was
induced with TNF (10 ng/ml) for 16 h followed by treatment
with cycloheximide (10 g/ml). Cells were fixed at various
times in 2% paraformaldehyde (Alfa Aesar), incubated at 4 °C
for at least 1 h, and analyzed on a FACSCalibur DxP8 (Cytek).
Flow cytometry data were analyzed by FlowJo X. Data were
normalized to 100% at time 0 and natural log transformed to
produce a linear half-life curve, from which the slope was cal-
culated. Two-tailed Z-tests were performed on averaged slope
values from at least four independent experiments. The equa-
tion t(1/2)  ln(2)/-slope was used to generate half-life values.
Time-lapse microscopy experiments were performed as
described (29).
Luciferase Assays—TZMBL cells (1  105) were transfected
with a total of 100 ng of DNA containing 1, 2, 5, or 10 ng of
Tat-expressing plasmids (WT, K51R, K71R, K51/71R) or empty
vector using X-tremeGENE 9 (Roche Diagnostics) as recom-
mended by the manufacturer. The cells were incubated for 48 h
and lysed in 1 Promega Passive Lysis Buffer. Luciferase assays
were processed with the Promega Dual-Luciferase Reporter
Assay System and measured on a Monolight 2010 luminome-
ter. Experiments were conducted with four independent bio-
logical replicates with technical duplicates and the statistical
significance of differences was determined with one-sided t
tests.
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Table S-1
Mass Spectrometry Ion Annotations
Annotation Ion Mass K71me Annotation Ion Mass K71me
a5 598.006 a11 1462.734
a17 2045.872 a20 2424.704
b8 1066.25 b3 341.807
b10 1378.103 b4 483.942
b11 1475.142 b5 639.89
b12 1573.218 b8 1080.918
b13 1700.565 b13 1714.677
b14 1757.853 c2 230.763
b16 1973.135 c7 941.733
b17 2074.58 c17 2105.045
b20 2438.38 c18 2242.017
c2 230.989 c20 2469.389
c3 358.925 c21 2557.104
c4 487.056 c22 2668.924
c7 2091.397 c23 2755.972
c17 2091.397 c24 2899.376 *
c18 2228.051 y3 376.818
c20 2456.066 y4 489.843
c21 2543.063 y6 674.883
c24 2884.518 * y8 940.85
y1 146.336 y13 1441.42
y3 375.866 y14 1538.768
y4 489.001 y15 1635.712
y8 940.094 y16 1791.815
y14 1538.294 y17 1947.602
y15 1635.481 y18 2103.61
y16 1791.304 y19 2232.26
y17 1948.125 y20 2387.675
y18 2104.376 y21 2545.118
y19 2232.49 y24 2970.69
y20 2388.953 M+H
+
3027.712 *
y22 2672.778
y23 2799.973
y24 2956.1
M+H
+
3013.764 *
* ions that contain K71me
Table S-1: Mass annotations for ions produced by MS/MS for the indicated figures. 
Figure 1D Left Figure 1D Right
Table S-2
Mass Spectrometry Ion Annotations
Annotation Ion Mass K71me Annotation Ion Mass K71me
a1 129.022 a1 59.492
a2 226.059 a8 830.203
a3 323.011 b1 87.782
a4 451.103 b5 556.341 *
a5 508.115 b7 770.89 *
a6 595.14 b9 1014.543 *
a7 723.253 c7 788.592 *
a8 824.378 c8 875.437 *
a9 961.359 M+H
+
1032.623 *
a11 1188.68
b2 254.011
b4 479.077
b5 536.121
b6 623.169
b7 751.173
b8 852.191
b9 989.36
c4 496.104
c8 869.144
y2 248.04 *
y3 361.104 *
y4 448.081 *
y5 547.128 *
y6 675.185 *
y7 812.298 *
y8 913.326 *
y13 1410.747 *
y14 1507.844 *
* ions that contain K71me
Table S-2: Mass annotations for ions produced by MS/MS for the indicated figures. 
Figure 3B Figure 3D
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